2026 ICD-10-CM Diagnosis Code P04.42Newborn affected by maternal use of hallucinogens

ICD-10-CM CodesP00–P96P00-P04P04

ICD-10-CM P04.42
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

P04.42 is a billable ICD-10-CM diagnosis code for newborn affected by maternal use of hallucinogens. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). Coders also document this condition as neonatal disorder caused by hallucinogenic agent transmitted via breast milk. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Neonatal abstinence syndrome and Newborn affected by maternal conditions or complications of labor/delivery.

Code Identity

ICD-10-CM Code
P04.42
Billable Status
Yes — Valid for Submission
Code Describes
Newborn affected by maternal use of hallucinogens
Short Description
Newborn affected by maternal use of hallucinogens
Same as the full description in the CMS dataset.
Parent Code
Newborn affected by maternal use of drugs of addiction

Code Classification

ChapterP00–P96Certain conditions originating in the perinatal period
SectionP00-P04Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery
CategoryP04Newborn affected by noxious substances transmitted via placenta or breast milk
This CodeP04.42Newborn affected by maternal use of hallucinogens

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Neonatal disorder caused by hallucinogenic agent transmitted via breast milk

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Type 2 Excludes

  • newborn affected by other maternal medication P04.1

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Absorption
      • drug NEC
        • addictive
          • through placenta (newborn)
            • hallucinogens
    • Newborn(infant) (liveborn) (singleton)
      • affected by
        • drugs of addiction
          • hallucinogens

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR PNL014
Neonatal abstinence syndrome
Default principal diagnosis: inpatient Yes · outpatient Yes
CCSR PNL010
Newborn affected by maternal conditions or complications of labor/delivery
Default principal diagnosis: inpatient No · outpatient No

Patient EducationClinical

Club Drugs

Club drugs are a group of psychoactive drugs. They act on the central nervous system and can cause changes in mood, awareness, and behavior. These drugs are most often used by young adults at bars, concerts, nightclubs, and parties.

The full article covers:

  • What are club drugs?
  • What are the different types of club drugs?
  • What are date rape drugs?
  • Are there steps I can take to protect myself from date rape drugs?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Code History & ChangesHistory

Replacement P04.42 replaces the following previously assigned code(s):

  • P04.49 - Newborn affected by maternal use of drugs of addiction
  • P04.49 - Newborn affected by maternal use of other drugs of addiction
FY 2019AddedAdded to the ICD-10-CM code setEffective October 1, 2018.
FY 2020–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About P04.42Overview

Is P04.42 (Newborn affected by maternal use of drugs of addiction) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report newborn affected by maternal use of hallucinogens on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.